Severe congenital dyserythropoietic anaemia type I: prenatal management, transfusion support and alpha-interferon therapy

Br J Haematol. 2000 Aug;110(2):420-3. doi: 10.1046/j.1365-2141.2000.02168.x.

Abstract

We report a case of congenital dyserythropoietic anaemia, type I, with severe pre- and postnatal manifestations. Exchange transfusions were required for fetal anaemia (3.5 g/dl) at 28 and 30 weeks of gestation. Transfusions were administered at birth (Caesarean section at week 35) and at regular intervals thereafter. At 14 months, alpha-interferon therapy was initiated (106 units three times a week). This resulted in stabilization of the haemoglobin at or above 11 g/dl and a reduction in the percentage of erythroblasts with ultrastructurally abnormal heterochromatin. After 9 months, the dose of alpha-interferon was decreased to 106 units twice a week. No relapse of anaemia was noted during an additional 4 months of follow-up.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anemia, Dyserythropoietic, Congenital / diagnosis
  • Anemia, Dyserythropoietic, Congenital / therapy*
  • Bone Marrow Examination
  • Exchange Transfusion, Whole Blood / methods*
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Iron Overload / etiology
  • Liver Function Tests
  • Pregnancy
  • Pregnancy Trimester, Second
  • Pregnancy Trimester, Third
  • Prenatal Diagnosis / methods*
  • Recombinant Proteins
  • Treatment Outcome

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins